Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paramethadione. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paramethadione SCHEMBL317346 | 0.92 | LMNA (0.56) | LMNAELANEPRTN3CTSGPGR | |
| Trimethadione SCHEMBL28882 | 0.84 | LMNA (1.00) | LMNAELANEPRTN3CTSGPGR | |
| Ethadione SCHEMBL13724326 | 0.78 | LMNA (0.70) | LMNAELANEPRTN3CTSGPGR | |
| Trimethadione SCHEMBL13724328 | 0.76 | LMNA (0.83) | LMNAELANEPRTN3CTSGPGR | |
| Metharbital SCHEMBL4885996 | 0.75 | LMNA (0.59) | LMNAELANEPRTN3CTSG | |
| SCHEMBL1363134 | 0.75 | LMNA (0.54) | LMNA | |
| SCHEMBL8363739 | 0.70 | LMNA (0.52) | LMNAPGR | |
| SCHEMBL14009928 | 0.67 | LMNA (0.54) | LMNAELANEPRTN3CTSGPGR | |
| Ethadione SCHEMBL35279 | 0.66 | ELANE (0.55) | LMNAELANEPRTN3CTSGPGR | |
| SCHEMBL13581344 | 0.65 | LMNA (0.42) | LMNAELANEPRTN3CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4351545-A1 | IDEBENONE IN THE TREATMENT OF DRUG RESISTANT EPILEPSY | Katholieke Universiteit Leuven (BE) | 2024-04-17 | — | — | EP | disclosed |
| EP-4333819-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | Katholieke Universiteit Leuven (BE) | 2024-03-13 | — | — | EP | disclosed |
| US-20230103644-A1 | TREATMENT OF EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-06 | — | — | US | disclosed |
| WO-2023041657-A1 | ALKYLATED HALOQUINOLINES FOR USE IN EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | WO | disclosed |
| EP-4121054-A1 | TREATMENT OF EPILEPSY | Katholieke Universiteit Leuven (BE) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022258629-A1 | IDEBENONE IN THE TREATMENT OF DRUG RESISTANT EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021185791-A1 | TREATMENT OF EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2021-09-23 | — | — | WO | disclosed |
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-103492389-B | Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases | 原真股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103644-A1 | TREATMENT OF EPILEPSY | SCN8A, KCNQ2, KCNQ5 | LMNA 2232/4885ELANE 1116/4885PRTN3 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.